Web Analytics
Invezz
2026-05-13 09:34:43

Injective jumps 15%: can INJ rally next target the $10 breakout?

Injective (INJ) price has climbed sharply over the past 24 hours, with the INJ token pumping by more than 15% as the wider crypto market received a fresh bid. This comes as Bitcoin looks to bounce above $81,000, targeting recent highs amid an upbeat sentiment that's lifting risk assets. Could the double-digit pump put bulls on course for more gains, or will bears show strength? Injective pumps, lead altcoins higher Injective price today puts it at the top as the biggest mover in the past 24 hours. The token is up more than 15%, with the double-digit bounce pushing INJ to highs last seen in early 2026. But Injective is not just outpacing all large-cap cryptocurrencies on the day; it's also dwarfing its peers. Currently, INJ is ahead of other notable gainers such as Celestia, Stacks, and Near Protocol. The broad strength suggests the rally is not isolated to one asset. However, Injective is one of the day’s standout gainers, largely driven by a sharp rise in activity. Per CoinMarketCap, daily trading volume increased by roughly 86% to more than $283 million within this period. During the latest session, INJ touched intraday highs above $5.55 as buyers stepped in aggressively. INJ is up 40% in the past week and nearly +90% in the past month. The surge has recently been supported by a mix of network-related catalysts. It includes progress around USDC and CCTP integration, which can improve interoperability and make the network more attractive for on-chain liquidity. https://twitter.com/injective/status/2054366523850944736 Injective’s deflationary tokenomics have also remained a key talking point among holders, helping reinforce the bullish narrative. Also on the radar are pre-IPO stocks coming onchain amid fresh interest in the assets. Injective price analysis As noted, the latest double-digit advance has pushed INJ to a five-month high last seen in January 2026. That breakout is significant, but it also raises the risk of near-term consolidation as traders will likely look at locking in gains after the sharp move. One indicator bulls might have eyes on is the relative strength index. The daily RSI, which is extended into overbought territory, may signal that Injective is due for a brief pullback or cooling period. When momentum indicators stretch too far too fast, price often pauses before attempting another leg higher. Injective price chart by TradingView If buyers can defend support on any retracement, INJ could remain on track to test the $6 to $8 resistance zone. Rallying to the $10 mark could embolden buyers further. For now, the combination of improving market sentiment, strong volume, and favorable network developments gives bulls a credible case. However, sustaining the rally will likely depend on whether INJ can absorb selling pressure and hold above recent support. If profit-taking intensifies, the first key support area to monitor is the recent breakout region around the $5 range. A deeper drop could expose lower support levels near the psychological $4-$3.50 area, where bulls may need to step in to preserve the broader uptrend. The post Injective jumps 15%: can INJ rally next target the $10 breakout? appeared first on Invezz

Get Crypto Newsletter
Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.